Marshall Wace
WHWK

Marshall Wace’s Whitehawk Therapeutics WHWK Stock Holding History

Marshall Wace’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,959
Closed -$164K – 3780
2025
Q4 		$164K Buy
+67,959
New +$156K ﹤0.01% 2632
2024
Q1 		– Sell
-21,400
Closed -$43.2K – 2874
2023
Q4 		$43.2K Buy
+21,400
New +$89.8K ﹤0.01% 2080
2023
Q1 		– Sell
-15,499
Closed -$199K – 3199
2022
Q4 		$199K Buy
+15,499
New +$202K ﹤0.01% 2703
2022
Q3 		– Sell
-19,564
Closed -$242K – 3885
2022
Q2 		$242K Sell
19,564
-71,521
-79% -$1.06M ﹤0.01% 3099
2022
Q1 		$1.54M Buy
91,085
+61,912
+212% +$1.19M ﹤0.01% 2209
2021
Q4 		$704K Buy
+29,173
New +$733K ﹤0.01% 2637
2019
Q2 		– Sell
-1,567
Closed -$21K – 1923
2019
Q1 		$21K Buy
+1,567
New +$67.4K ﹤0.01% 1629

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Marshall Wace's WHWK Position: Q1 2026 in Review

Marshall Wace sold out of Whitehawk Therapeutics (WHWK) in Q1 2026, closing a stake of 67,959 shares — an estimated $164K sold.

Marshall Wace first reported a position in WHWK in Q1 2019 and held it in 7 quarters. The position peaked at $1.54M in Q1 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Marshall Wace reported no remaining Whitehawk Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 67,959 Whitehawk Therapeutics shares in Q1 2026, an estimated $164K.
  • Marshall Wace first reported a position in Whitehawk Therapeutics in Q1 2019 and held it in 7 quarters.
  • Marshall Wace's Whitehawk Therapeutics position peaked at $1.54M in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.